Controlled trial with a monthly combination injectable contraceptive in Europe.
In a controlled, multicenter trial conducted in Europe, the safety and efficacy of a monthly injectable combination hormone contraceptive were found to be comparable to those of an oral contraceptive. There were no contraceptive failures in either arm of the trial. The incidence and types of side-effects were similar. The rates of patient satisfaction in the monthly injectable and oral contraceptive arms of the study were also comparable; both exceeded 90%. The results from the European study are consistent with clinical trials conducted elsewhere and support the conclusion that the monthly combination injectable contraceptive represents a desirable new birth control method. Data from the 24-week interim analyses are presented.
Brucker
C
C
Section of Gynecological Endocrinology and Reproductive Medicine, University of Ulm, Ulm, Germany.
D000293:Adolescent; D000328:Adult; D003267:Contraception; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects*; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005060:Europe; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects*; D008875:Middle Aged; D011247:Pregnancy; D011446:Prospective Studies; D013997:Time Factors
D003277:Contraceptives, Oral, Combined; D004958:Estradiol; C007630:estradiol 17 beta-cypionate; D017258:Medroxyprogesterone Acetate